Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Naphthoquine + azithromycin is a fixed-dose combination drug formulated in a 1:1 ratio for the prophylaxis of malaria. Naphthoquine is an antimalarial agent with a long elimination half-life (>20 days), providing extended protection against Plasmodium species. Azithromycin is a macrolide antibiotic that also exhibits delayed antimalarial effects by targeting the apicoplast of Plasmodium parasites. The combination has demonstrated high efficacy as monthly single-dose prophylaxis, offering over 90% protective efficacy against all malaria species within one month and complete protection against relapsing malaria caused by Plasmodium vivax and Plasmodium ovale. Both agents have favorable safety profiles; transient elevation of liver aminotransferases was observed but not statistically significant compared to placebo[1][3]. The synergistic interaction between the two drugs enhances their antimalarial activity[2][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on naphthoquine + azithromycin.